Filing Details

Accession Number:
0001354488-16-008627
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-12-06 15:26:01
Reporting Period:
2016-12-02
Filing Date:
2016-12-06
Accepted Time:
2016-12-06 15:26:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1006281 Protalix Biotherapeutics Inc. PLX Biological Products, (No Disgnostic Substances) (2836) 650643773
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1444043 Camber Capital Management Llc 101 Huntington Avenue
Suite 2101
Boston MA 02199
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-12-02 2,500,000 $0.32 10,775,000 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
Footnotes
  1. Securities reported herein for Camber Capital Management LLC (the "LLC" ) represent Common Stock beneficially owned and held of record by Camber Capital Master Fund, L.P. (the "Master Fund"), another private investment fund (the "Fund") and one managed account (the "Managed Account") for which the LLC serves as the investment manager. Stephen DuBois is the managing member of the LLC and managing member of the general partner for the Fund and the Master Fund. The LLC, the Master Fund, the Fund, the Managed Account, general partner and Mr. DuBois (the "Reporting Persons") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 21, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein.
  2. Of the securities reported for this transaction, 2,413,466 shares of Common Stock were sold for the account of the Master Fund, 16,998 shares of Common Stock were sold for the account of the Fund, and 69,536 shares of Common Stock were sold for the account of the Managed Account.
  3. As of the closing of trading on December 06, 2016, 10,402,037 shares of Common Stock were held for the account of the Master Fund, 73,262 shares of Common Stock were held for the account of the Fund, and 299,701 shares of Common Stock were held for the account of the Managed Account.